Tissue Regenix, (AIM: TRX) a medical technology company focused on the development and commercialisation of acellular tissue replacement products to address the chronic global shortfalls in donor tissue availability, announces that it has joined the AIM market of the London Stock Exchange today via a reverse takeover of Oxeco Plc. This follows the passing on 28 June 2010 of the resolutions relating to Oxeco's acquisition of Tissue Regenix Ltd.
